Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2025

Ixekizumab and malignant neoplasms A pooled analysis of data from 25 randomized clinical trials

Merola et al. JAMA Dermatol 2025; 9:e252056

Papp KA,

Zhu D,

Inman E,

Grace E,

Merola et al. showed that the safety profile of ixekizumab (IXE) supports its long-term use in patients with PsO, PsA, or axSpA, without an increased risk for malignant neoplasm development. Merola et al. investigated the incidence rates of malignant neoplasms among patients with PsO, PsA, or axSpA who underwent long-term treatment with IXE, an IL- 17A antagonist.

Keywords:

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis 2025;25:01024-6 doi: 10.1016/j.ard.2025.05.014

Rudi T,

Schaefer et al. showed that treatment with JAKis (predominantly BARI and TOF) was associated with an increased HR of malignancies compared to treatment with bDMARDs in the overall study cohort, consistent with results from the ORAL surveillance trial. To better understand the complex role of JAKis in cancer development in RA patients, Schaefer et al. estimated the effects of JAKis compared to bDMARDs on the risk of malignancy (excluding NMSC) in patients with RA.

Keywords:

April 2025

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

RMD Open. 2025;11:e005026. doi: 10.1136/rmdopen-2024-005026.

Ink B,

White K,

Mease et al. found that bimekizumab demonstrated a favourable long-term safety profile in patients with axSpA and PsA.

Keywords:

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

RMD Open. 2025;11:e005033. doi: 10.1136/rmdopen-2024-005033.

Choy EH,

Faes M,

Mariette et al. investigated the long-term safety of filgotinib with regard to MACE, VTE and malignancy across RA and UC clinical trial populations. Rates of these events remained low overall, with some increases observed in patients aged 65 years and older.

Keywords:

March 2025

Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis

Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005

Zhao SS,

Riley D,

Hernandez G,

Alam U

Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.